Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these...

Area of Science:

• Cardiology
• Lipidology
• Pharmacology

Background:

• Elevated baseline triglycerides (TG) are a significant contributor to residual atherosclerotic cardiovascular disease (ASCVD) risk, especially in patients with type 2 diabetes mellitus, metabolic syndrome, and obesity.
• Standard LDL-C reduction therapy alone is insufficient for optimal treatment in these patients.
• Previous trials with other agents failed to show significant cardiovascular event reduction when added to statins.

Purpose of the Study:

• To highlight the importance of elevated TG in patients with well-controlled LDL-C on statins.
• To describe the findings and clinical implications of the REDUCE-IT trial regarding icosapent ethyl.
• To emphasize the need for treatment beyond LDL-C lowering for hypertriglyceridemic patients.

Main Methods:

• Review of clinical data and landmark trials, focusing on the REDUCE-IT trial.
• Analysis of 8179 participants with high ASCVD risk, elevated baseline TG, and controlled LDL-C.
• Evaluation of icosapent ethyl (ethyl eicosapentaenoic acid) at 4 g daily dosage.

Main Results:

• The REDUCE-IT trial demonstrated that icosapent ethyl significantly reduced ASCVD events.
• Significant reductions were observed in the primary endpoint, cardiovascular death, and key secondary endpoints.
• Icosapent ethyl provided ASCVD event reduction beyond the effects of statin therapy.

Conclusions:

• Elevated TG in patients with controlled LDL-C represents a significant residual ASCVD risk.
• Icosapent ethyl is a novel therapeutic option that unequivocally reduces ASCVD events in high-risk patients.
• These findings necessitate a re-evaluation of management strategies for hypertriglyceridemic patients.